CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311761 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Luke C Dutton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Services, Royal Veterinary College, Hatfield, London, United Kingdom. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Cardiomyopathy, Hypertrophic, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Winn Feline Foundation, Boehringer Ingelheim.
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is the most common heart disease in domestic cats, often leading to congestive heart failure and death, with current treatment strategies unable to reverse or prevent progression of the disease. The underlying pathological processes driving HCM remain unclear, which hinders novel drug discovery. The aim of this study was to generate a cellular model of the feline HCM-causing MYBPC3 mutation R820W. Using CRISPR/Cas9 gene editing we introduced the R820W mutation into a human induced pluripotent stem cell (iPSC) line. We differentiated both homozygous mutant clones and isogenic control clones to cardiomyocytes (iPSC-CMs). Protein quantification indicated that haploinsufficiency is not the disease mechanism of the mutation. Homozygous mutant iPSC-CMs had a larger cell area than isogenic controls, with the sarcomere structure and incorporation of cMyBP-C appearing similar between mutant and control iPSC-CMs. Contraction kinetic analysis indicated that homozygous iPSC-CMs have impaired relaxation and are hypocontractile compared to isogenic control iPSC-CMs. In summary, we demonstrate successful generation of an iPSC model of a feline MYBPC3 mutation, with the cellular model recapitulating aspects of HCM including cellular hypertrophy and impaired relaxation kinetics. We anticipate that further study of this model will lead to improved understanding of the disease-causing molecular mechanism, ultimately leading to novel drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science and Services, Royal Veterinary College, Hatfield, London, United Kingdom.
ORCID-Profile: Luke C Dutton, Jayesh Dudhia
Förderung
- Wellcome Trust
- Winn Feline Foundation
- Boehringer Ingelheim
Zitieren
APA
Dutton, L. C., Dudhia, J., Guest, D. J., & Connolly, D. J. (2024). CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation. PLOS ONE. https://doi.org/10.1371/journal.pone.0311761
Vancouver
Dutton LC, Dudhia J, Guest DJ, Connolly DJ. CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation. PLOS ONE. 2024. doi:10.1371/journal.pone.0311761
BibTeX
@article{Dutton2024,
author = {Dutton, Luke C and Dudhia, Jayesh and Guest, Deborah J and Connolly, David J},
title = {CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311761}
}
EUVIMED